Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 29c ; Offers Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.56), $0.29 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $246 million versus the consensus estimate of $199.24 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2026 revenue of $875-900 million, versus the consensus of $811.3 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Shoals ships PowerHub units for 1.1 GW U.S. battery project
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business